New to MyHealth?
Manage Your Care From Anywhere.
Access your health information from any device with MyHealth. You can message your clinic, view lab results, schedule an appointment, and pay your bill.
ALREADY HAVE AN ACCESS CODE?
DON'T HAVE AN ACCESS CODE?
NEED MORE DETAILS?
MyHealth for Mobile
Current understanding of the Wiskott-Aldrich syndrome and prospects for gene therapy.
Current understanding of the Wiskott-Aldrich syndrome and prospects for gene therapy. Expert review of clinical immunology Trifari, S., Marangoni, F., Scaramuzza, S., Aiuti, A., Roncarolo, M. G., Dupré, L. 2007; 3 (2): 205-215Abstract
Gene therapy, based on the transplantation of genetically corrected autologous hematopoietic stem cells (HSCs), has proven to be an effective therapeutic approach as an alternative to allogenic HSC transplantation for the cure of severe combined immunodeficiencies (SCID). In this article, the recent preclinical studies aiming towards gene therapy trials for the Wiskott-Aldrich syndrome (WAS), a life-threatening immunodeficiency characterized by infections, hemorrhages, autoimmune disorders and lymphomas, will be reviewed. An update of the safety and efficacy data obtained in studies performed in murine disease models and in cells from WAS patients will be presented. Based on these data and on the clinical results of the recent trials for SCID, the most critical issues regarding the implementation of a gene therapy approach for WAS will be discussed.
View details for DOI 10.1586/1744666X.3.2.205
View details for PubMedID 20477109